- Search CSN:
- Members: Login to search all areas
- Not a member? Click here to search public areas
|
Jan 12, 2015 - 2:12 am
http://news.bms.com/press-release/checkmate-017-phase-3-study-opdivo-nivolumab-compared-docetaxel-patients-second-line-s Superior preliminary data for ns lung ca. FDA should approve soon. Renal cell cancer trial preliminary data PD-1 Opdivo vs Affinitor Everolimus should come summer 2015, hopefully and hopefully will be superior and quickly FDA approved.
http://www.marketwatch.com/story/checkmate--017-a-phase-3-study-of-opdivo-nivolumab-compared-to-docetaxel-in-patients-with-second-line-squamous-cell-non-small-cell-lung-cancer-stopped-early-2015-01-11 |
Joined: Mar 2012
Thanks for the info.. let's
Thanks for the info.. let's hope it works out that way!